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Abstract
In vitro and in vivo assessment of safety and efficacy are the essential first steps in developing
nanoparticle-based therapeutic systems. However, it is often challenging to use the knowledge
gained from in vitro studies to predict the outcome of in vivo studies since the complexity of the
in vivo environment, including the existence of flow and a multicellular environment, is often lack-
ing in traditional in vitro models. Here, we describe a microfluidic co-culture model comprising
4T1 breast cancer cells and EA.hy926 endothelial cells under physiological flow conditions and its
utilization to assess the penetration of therapeutic nanoparticles from the vascular compartment
into a cancerous cell mass. Camptothecin nanocrystals (310 nm in length), surface-functionalized
with PEG or folic acid, were used as a test nanocarrier. Camptothecin nanocrystals exhibited only
superficial penetration into the cancerous cell mass under fluidic conditions, but exhibited cytotox-
icity throughout the cancerous cell mass. This likely suggests that superficially penetrated
nanocrystals dissolve at the periphery and lead to diffusion of molecular camptothecin deep into
the cancerous cell mass. The results indicate the potential of microfluidic co-culture devices to
assess nanoparticle-cancerous cell interactions, which are otherwise difficult to study using stand-
ard in vitro cultures.
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1 | INTRODUCTION
Canonical drug delivery research usually commences with the valida-
tion of a carrier or a drug using in vitro static cell cultures in which cells
are grown in 2D monolayers and are subjected to the drug and subse-
quently tested through a variety of established methods for cellular
uptake and cytotoxicity effects. If efficacy and toxicity outcomes in the
static cultures are deemed satisfactory, then the carriers are advanced
to in vivo studies. Currently, on average, five compounds from the ini-
tial pool of 5,000–10,000 enter clinical trials, and only one becomes a
successful FDA approved drug.1 Since carriers often alter the drug’s
efficacy and toxicity, drug-carrier combinations must also go through
the same rigorous validation and approval process. This approach limits
the likelihood and speed of translation of in vitro foundational research
to in vivo outcomes.2
The knowledge gap between the performance of the carriers in
vitro and in vivo is often difficult to bridge due to the disparate nature
of the two methods of studies. In vitro cell cultures are typically con-
ducted under static conditions and use a monoculture. In vivo studies,
by definition, involve a dynamic environment where a multitude of
contributing factors could collectively dictate the outcome and it is
often difficult to isolate confounding elements and elucidate the mech-
anistic differences between in vivo and in vitro observations.
Static 2D monolayer cell cultures do not fully account for the
impact of physiologically relevant shear forces on carriers. Physiological
flows in blood and interstitium are often laminar—dominated mostly by
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viscous forces and diffusive mixing within higher micro- and macro-
regime vessel sizes.3 In addition, standard in vitro cultures lack the mul-
ticellular environment containing complex extracellular matrix, which is
characteristic of tissues. These physical parameters strongly impact car-
rier performance in vivo, for example, the carrier’s ability to extravasate
and accumulate at the cancerous cell mass site.
Microfluidic devices offer the potential to bridge the gap between
the standard in vitro and in vivo models for drug delivery and discovery
because of their ability to integrate physiological processes which are
often overlooked or not directly accounted for in traditional in vitro
methods.4 In comparison to traditional in vitro models, data from
microfluidics devices can provide a more accurate and comprehensive
prediction of how well a carrier will perform in vivo.
In this study, we utilized an idealized co-culture microfluidic device
(ICD) with an inner tissue culture chamber and two flanking outer vas-
cular channels connected to the tissue chamber via micron sized
pores.5 The inner tissue culture chamber of the ICD was cultured with
murine breast cancer cell line, 4T1, and the outer vascular channels
were cultured with the human umbilical vein endothelial cell line,
Eahy.926. Cancerous and healthy cells were cultured in 3D in the tis-
sue chamber and exposed to camptothecin (CPT) nanocrystals, with
rod-shaped morphology, under physiologically relevant shear stresses
found within micro-domain sized vessels.6 Cells subjected to nontoxic
and nonimmune reactive nanoparticles under physiologically relevant
shear stresses are known to induce cell death due to the physical and
mechanical interactions of particles and cell surfaces which are
enhanced and impart a cytotoxic effect.7 The devices were used to
monitor penetration and efficacy of the nanocrystals within the cancer-
ous cell mass site after short infusion time periods, akin to bolus
injections.
The choice of therapeutics (camptothecin nanocrystal) was moti-
vated by our previous studies, which demonstrated the benefits of
rod-shaped nanoparticles over spheres.8 Nanocrystals provide a unique
ability to increase drug loading as well as control its release kinetics.9
The crystalline nanorods used here comprise entirely of camptothecin,
a Topo I inhibitor. Hydrophobic drugs have traditionally posed a chal-
lenge in drug delivery due to their poor solubility and dependence on
amphiphilic carriers for their distribution.10 Nanocrystals posit an alter-
native to the traditional hydrophobic drug carriers since they are
entirely comprised of the hydrophobic drug; creating a high concentra-
tion of drug in a localized area.11–13 Camptothecin nanocrystals were
used either in their bare form or surface-modified to display PEG or
PEG-folic acid. Folic acid was chosen for its ability to target the folic
acid receptor on 4T1 cells.14–16
2 | METHODS
2.1 | Preparation of camptothecin nanocrystals
All CPT nanocrystals were prepared using the solvent diffusion
method. Unmodified camptothecin nanocrystals (CPT-UM) were used
as a base model. To prepare PEG-modified camptothecin nanocrystals
(CPT-PEG), DSPE PEG2K amine was added concurrently during the
formation of the CPT nanocrystals. Folic acid-modified camptothecin
nanocrystals (CPT-FA) were prepared by first conjugating DSPE
PEG2K amine to folic acid and then adding it during CPT nanocrystal
preparation.
To make CPT nanocrystals, 5 ml of 0.8 mg/ml of CPT (Sigma
Aldrich) in DMSO solution was pipetted dropwise into a 120 ml water
mixture containing 1% w/w alpha—tocopherol (Sigma). The mixture
was stirred at 800 rpm under constant ultrasonication at room temper-
ature (228C) for 1 hr. CPT-UM nanocrystals formed at the boundary
where DMSO diffused into the water. The CPT-UM nanocrystals were
then centrifuged three times at 208C with milliQ water (18.2 X) at
3,500 rpm. The concentration of CPT-UM nanocrystals was deter-
mined by dissolving the nanocrystals in DMSO and reading the absorb-
ance at 366 nm using a spectrophotometer (Tecan M220 Infinite Pro)
and a CPT calibration curve.
To prepare CPT-PEG nanocrystals, a mixture of 5 ml of 0.8 mg/ml
CPT and 3.2 mg/ml DSPE PEG2K Amine (Avanti Polar Lipids) was
added to the 1% alpha—tocopherol water mixture solution, all subse-
quent steps for preparation, purification, and quantification described
above for CPT-UM nanocrystal preparation were followed. The suc-
cessful incorporation of DSPE PEG2K amine was validated via X-ray
diffraction (XRD) of DSPE PEG2K amine, CPT, and alpha-tocopherol in
their free powder form compared to the CPT-PEG construct (Panalyti-
cal Empyrean Powder Diffractometer). CPT was quantified using
absorbance at 366 nm as described above. DSPE PEG2K amine was
quantified via Phosphorous solution state NMR (P31) (Varian 600
MGHz). Spectra were analyzed using Mnova software; peaks were
integrated and compared to a K2HPO4 standard to determine quanti-
ties of phosphorous present. Phosphorous and DSPE PEG2K Amine
are present in 1:1 molar ratios enabling us to quantify the milligrams of
DSPE PEG2K amine present from phosphorous signals.
To prepare CPT-FA, DSPE PEG2K amine-FA conjugates were pre-
pared first. Specifically, 4.5 mg of folic acid was dissolved in 500 ml of
DMSO. This solution was then added to 100 ml of 5 mg/ml EDC
(Sigma) in DMSO solution. It was then vortexed and rotated for 30 min
at room temperature. To this solution, 19 mg of DSPE PEG2K amine
dissolved in 500 ml of DMSO was added; this combined mixture was
vortexed and rotated overnight at room temperature. The DSPE
PEG2K amine—folic acid conjugate was then purified with a HyperSep
C18 octadecyl uncapped bonded silica column, with an acetonitrile—
milliQ H2O (18.2 X) 5–50% v/v gradient. Polymer-folic acid conjugate
eluents were then analyzed via Matrix Assisted Laser Desorption
Ionization-Mass Spectrometery (MALDI-MS, Microflex LRF A Bruker)
and with FTIR set to 24 scans and taken in acetonitrile (Magna IR 850
Nicolet). FTIR spectra were analyzed in the fingerprint region using
OMNIC software.
To incorporate folic acid into CPT crystals, 5 ml of 0.8 mg/ml of
CPT (Sigma Aldrich) in DMSO solution was pipetted dropwise into a
120 ml water mixture containing 1% w/w alpha—tocopherol (Sigma).
The 20% acetonitrile—milliQ H2O (18.2 X) eluent containing PEG-FA
conjugate was then added dropwise to this solution and the overall
mixture containing CPT, DSPE PEG2K amine, and FA was stirred at
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800 rpm with constant ultrasonification at room temperature (228C)
for 1 hr. After 1 hr, the CPT-FA nanocrystals were then centrifuged
three times at 208C with milliQ water (18.2 X) at 3,500 rpm. The pres-
ence of folic acid was quantified using absorbance at 290 and 370 nm,
and CPT was quantified using fluorescence at 366/434 nm—both uti-
lized a spectrophotometer (Tecan M220 Infinite Pro) and a CPT and FA
calibration curve at all respective wavelengths. DSPE PEG2K Amine
was quantified using P31 NMR as described above in CPT-PEG
constructs.
Morphologies of CPT, CPT-PEG, and CPT-FA nanocrystals were
analyzed using a scanning electron microscope (SEM). Surface charges
of all nanocrystalline scaffolds suspended in 1x PBS pH 7.4 were meas-
ured as zeta potential using a Nanoseries-Zetasizer (Malvern).
2.2 | CPT release from CPT-UM and CPT-PEG
nanocrystals
Drug release of CPT from CPT-UM and CPT-PEG was achieved using
Slide-A-Lyzer MINIdialysis Devices of 3.5k MWCO (Life Technologies,
Grand Island, NY). Freshly prepared nanocrystals were resuspended in
500 ll of citric acid buffered solutions pH 3 and 5, a PBS buffered
solution of pH 7.4, RPMI cell culture media containing 10% FBS and
1% Pen–Strep, and lastly, 100% FBS in dialysis cups. Dialysis devices
were inserted into microcentrifuge tubes containing 1 ml of the corre-
sponding solution placed at 378C and set on an orbital shaker at
100 rpm. At indicated time points, aliquots of CPT were removed from
the microcentrifuge tubes and CPT concentration as determined via
absorbance. Corresponding solutions were then added at each time
point to maintain a constant volume.
2.3 | Cell culture
All cell lines were commercially obtained from ATCC and were grown
in a humidified incubator with 5% CO2 at 378C. Endothelial cell line,
EA.hy926 cells, were cultured using DMEM medium supplemented
with 10% FBS and 1% penicillin–streptomycin (Pen–Strep). Murine
mammary tissue cancerous cell line, 4T1 cells, were cultured using
RPMI-1640 medium supplemented with 10% FBS and 1% Pen–Strep.
2.4 | Idealized co-culture microfluidic devices
nanocrystalline penetration studies
Idealized co-culture microfluidic devices (ICD’s) were purchased from
SynVivo (Cat#102016). See Figure 1. Dimensions were set to the fol-
lowing: an outer channel (OC) of 200 microns, a travel distance (T) of
50 microns, slit spacing (Ss) of 50 microns, and a slit width (Ws) of 2
microns.
ICD’s outer vascular channels were coated with 100 mg/ml human
fibronectin (Thermo Fisher), subjected to 5 PSI N2 (laboratory grade)
for 15 min, and incubated in a humidified incubator with 5% CO2 at
378C in preparation for seeding with EA.hy926 cells. A schematic of
the ICD’s is provided below. Once cultured, EA.hy926 cells were
allowed to incubate for 4 hr to attach to the outer vascular channels of
the ICDs before changing the media using a syringe pump set at 4 ml/
min (KD Scientific Inc.). Inner tissue culture chambers of ICDs were
subsequently coated with a 20% v/v Matrigel (Corning) cell culture
medium slurry. To facilitate polymerization of the Matrigel, ICDs were
incubated with 5% CO2 at 378C for 1 hr before infusion of freshly pre-
pared CPT-UM nanocrystals. For the duration of the experiments,
Eahy.926 cells received media changes every 12 hr at 2 ml/min for 10
min using a syringe pump (KD Scientific Inc.). Freshly prepared CPT-
UM nanocrystals were then infused through the outer vascular chan-
nels at 1 mg/ml, 4 ml/min, for 15 min and imaged at 48 hr post infusion
using an inverted microscope (Olympus CKX-41). Near-UV and FITC
filters were used to obtain images of CPT-UM nanocrystal penetration
and cell autofluorescence respectively.
2.5 | In vitro cytotoxicity of CPT-UM, CPT-PEG, and
CPT-FA
In vitro activity of CPT-UM, CPT-PEG, and CPT-FA nanocrystals in
4T1 cells was analyzed using Calcein AM and Ethidium homodimer-1
of the Live-Dead assay kit (Invitrogen). 4T1 cells were cultured in 96-
well plates at a density of 50,000 cells in 100 ll of RPMI, 10% FBS, 1%
Pen–Strep. Cells were allowed to attach overnight before undergoing
exposure of nanocrystals for short incubation times. 4T1 cells in short
incubation experiments were treated with nanocrystals for 3 hr then
washed with RPMI, 10% FBS, 1% Pen–Strep and allowed to incubate
for 48 hr before being assayed. All nanocrystal treatments were sub-
jected to a serial dilution series starting with 1 mg/ml of CPT as deter-
mined by absorbance and fluorescence methods described above. The
following controls were used in 4T1 cells: free CPT (Sigma), Folic Acid
(Fisher), and DSPE PEG2K amine (Avanti Polar Lipids Inc.). At 48 hr,
4T1 live cells were measured using the Live-Dead Assay Kit (Invitrogen)
and analyzed using a plate reader (Tecan M220). For quantification of
the number of live cells, 1 lM of Calcein AM was added to the cells
and incubated for 30 min before taking fluorescence intensity readings
(ex./em. 495/530 nm). Fluorescence backgrounds were subtracted
from each reading. Assays were performed in quadruplicate in three
FIGURE 1 Cartoon depictions of the idealized co-culture
microfluidic devices (SynVivo), channels in blue represent the outer
vascular while red channels represent the inner tissue culture
channel used in this study for breast cancer cell culture. A zoomed
in image of the central tissue culture chamber better depicts the
slits connecting the outer and inner tissue culture channels
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independent experiments. The results are expressed in IC50 format
determined from dose response curves generated for each nanocrystal-
line scaffold via the Chou-Talalay method.
2.6 | Idealized co-culture microfluidic devices
The inner and tissue culture chamber and outer vascular channels of
the ICDs were prepared as described above for EaA.hy.926 cell seed-
ing. Unlike the ICDs used for nanocrystal penetration studies, the inner
tissue culture chambers of the ICDs were cultured with 4T1 cells 24 hr
post EAa.hy.926 seeding. 4T1 cells were cultured in a 20% v/v Matrigel
(Corning) cell culture medium slurry. 4T1 cells were allowed 4 hr to
adhere to the outer inner tissue culture chambers of the ICDs before
conducting a 100% cell culture media change using a syringe pump set
at 4 ml/min (KD Scientific Inc). EA.ahy.926 and 4T1 cell cultured ICDs
were then maintained in a humidified incubator with 5% CO2 at 378C.
Every 12 hr Eahy.926 and 4T1 cells received 100% media changes
with their respective media at 2 ml/min until all experiments were
terminated.
3 | RESULTS
3.1 | Synthesis and characterization of camptothecin
nanocrystals
Rod-shaped CPT nanocrystals were prepared using the solvent diffu-
sion method and were visualized using SEM (Figure 2).
The dimensions of the nanocrystalline rods are reported in Table
1; the average long and short axes of these particles are 270 nm, 67
nm for the CPT-UM, 348 nm, 54 nm for the CPT-PEG, to 395 nm, 81
nm for the CPT-FA. In the case of CPT-PEG and CPT-FA, the w/w
ratio of CPT/DSPE PEG2K amine and CPT/FA are 0.25 and 0.88,
respectively. The percent yield of PEG retained on the surface of the
CPT nanocrystal was approximately 84%. CPT-UM, CPT-PEG, and
CPT-FA nanocrystals all possess negative zeta potentials, although the
CPT-PEG and the CPT-FA constructs are significantly more positive
compared to CPT-UM (Table 1). SEM images of the constructs depict
aggregation which is attributed to the drying and coating method of
the nanocrystals on the SEM mounts. Overall the morphology of par-
ticles was not altered by surface modification, which was expected
since the surface coating is expected to be thin.
Mass spectra of the CPT-UM construct showed the parent peak
at 348 m/z. CPT-PEG spectra depicted the polymeric PEG signature
centered around 1,500 m/z. Peaks labeled in the zoomed inlet are
44 m/z apart from one another corresponding to the weight of one
PEG unit. CPT-FA spectra also show a polymeric signature centered
around 1,500 m/z. Lastly, mass spectra of the DSPE PEG2K amine-
FA conjugate has polymeric signatures ranging from 800 to
1,700 m/z (Figure 3).
XRD spectra of all constructs verified the nanocrystalline nature of
the particle scaffolds. See Figure 4. The distinct signatures of CPT-UM,
CPT-PEG, and CPT-FA signified that the three constructs are nanocrys-
talline in nature, and they possess unique packing structures. Most sig-
nificantly, it is apparent that CPT-PEG is not a CPT-UM nanocrystal
encased in a liposome but has the lipid tail of DSPE PEG2K amine
either anchored within the hydrophobic regimes of CPT-UM crystal, or
the DSPE PEG2K Amine has physically adhered to the nanocrystalline
surface in such a way it significantly alters the crystalline pattern and
creates a distinction between CPT-UM and CPT-PEG. This distinction
carries over and is further enhanced by the conjugation of folic acid to
DSPE PEG2K Amine resulting in distinct nanocrystalline patterns for all
three constructs.
DSPE PEG2K amine-FA conjugates were analyzed using Fourier
transform infrared spectroscopy (FTIR). Mass spectra of dissolved CPT-
FA nanocrystals were taken in conjunction with FTIR spectra and
absorbance measurements for folic acid at 290 nm were used to verify
and quantify the presence of the folic acid in the construct.
The release of free CPT from all three nanocrystals was meas-
ured. CPT-PEG was stable and did not break down releasing free
CPT during the 5-day extended analysis in buffered solutions of pH
FIGURE 2 Scanning electron microscopy showing the morphology and size of CPT-UM, CPT-PEG, and CPT-FA
TABLE 1 Z—Size averages with polydispersity indices, the Zeta
potential, and the width as determined by ImageJ from SEM images
are reported here
Sample Z—size average (nm) Zeta potential (mV) Width (nm)
CPT-UM 271.7
PDI: 0.174
230.466.61 67617
CPT-PEG 348.0
PDI: 0.155
29.6664.94 5469
CPT-FA 395.2
PDI: 0.172
24.6763.57 81621
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7, pH 5, and pH 3. Release studies conducted in cell culture media
(DMEM, 10% FBS, 1% penicillin–streptomycin) revealed CPT-PEG
broke down and released 34% of the CPT encased in the construct.
These values represent a significant decrease in the release of free
CPT for the CPT-PEG construct compared to the release from CPT-
UM. The release of CPT from CPT-UM construct was observed in
buffered solutions pH 7, pH 5, and pH 3 but to a far lesser extent
than in cell culture media for the same construct. The above results
FIGURE 3 Matrix assisted laser desorption ionization-mass spectroscopy (MALDI-MS) spectra of (a) CPT UM (b) CPT-PEG (c) CPT-FA,
and (d) DSPE PEG2K AMINE-FA conjugate
FIGURE 4 X-ray diffraction spectroscopy of (Green) CPT-FA (Blue) CPT-PEG and (Red) CPT-UM crystals. Inlet depicts zoom-in of the
CPT-PEG and CPT UM spectral patterns
272 | JARVIS ET AL.
are consistent with the slight solubility, approximately 3 mg/ml, of
CPT in buffered pH 3 solution.17,18 Hundred percent release of CPT
was observed when CPT-UM particles were placed in 100% FBS
and allowed to incubate for 5 days under constant orbital shaking.
All release data for CPT-UM and CPT-PEG were normalized to this
positive control. The delayed effect of CPT release was attributed
to the surface coating (Figure 5).
3.2 | In vitro cell growth inhibition by CPT nanocrystal
constructs
The effects of CPT-UM, CPT-PEG, and CPT- FA on in vitro growth
inhibition of 4T1 cells were assessed. The effects of folic acid and
free CPT were also tested for in vitro growth inhibition of 4T1 cells.
PEG and its fatty acid derivatives are nonimmunogenic and biologi-
cally inert.19 Folic acid by itself exhibited minimal toxicity regard-
less of exposure time. Short exposure time experiments which, are
more applicable toward the framework of microfluidic device
experiments had IC50 values of 26 mg/ml, 650 mg/ml, and 560 mg/
ml, respectively for the CPT-UM, CPT-PEG, and CPT-FA constructs
(Table 2).
3.3 | Cell growth inhibition in idealized co-culture
microfluidic devices
The effect of all CPT constructs on in vitro growth inhibition of 4T1
cells was assessed within idealized co-culture microfluidic devices. Sig-
nificant effect of CPT-UM on cell viability was observed (Figure 6). In
control devices (not exposed to CPT-UM), a large population of live
cells (green) was seen in endothelial chambers as well as within the
cancer cell chamber (Figure 6a). A certain fraction of dead cells was
seen as well, especially within the cancer cell chamber. This could be
attributed to moderate cell death during the seeding process which can
compromise cell membrane integrity as the cells are transported
through the syringe needle at relatively fast flow rates in a top down
fashion resulting in relatively high impact forces at the moment of
seeding. A significantly elevated population of dead cells was observed
in CPT-UM-treated ICDs (Figure 6b). The effect was clear in the endo-
thelial chamber as well as within the cancer cell chamber. Qualitative
and quantitative analyses of fluorescent images taken of test ICDs sub-
jected to CPT-UM nanocrystal flow reveal a significant difference in
dead/live cell fluorescence intensity ratios measured from cell viability
assays of 4T1 cells within the inner tissue culture chamber.
Effect of CPT nanocrystals on cells was quantified as the differ-
ence in the intensity ratio of dead/live cells between CPT-treated and
control cells (nontreated) (Figure 7). CPT-UM yielded the most promi-
nent effect on cell viability, both in the endothelial as well as cancer
cell chamber. CPT-UM yielded about threefold enhancement in dead/
live ratio compared to controls. The effect in the vascular channel was
FIGURE 5 Cumulative release (%) of Camptothecin (CPT)
measured at 366 nm in pH 7.4, pH 5, pH 3, and DMEM containing
10% FBS and 1% Pen–Strep (Cell Culture Medium) at 378C under
constant orbital shaking for CPT-UM crystals and CPT-PEG
crystals. Percent cumulative release calculated as percentage of
release compared to 100% release of CPT-UM crystals in 100%
FBS under the same physical conditions
TABLE 2 4T1 cell line IC50 values reported here for CPT-UM,
CPT-PEG, and CPT-FA for short exposures of t23 hr with end
time points set at 48 hr. IC50 values were determined using
Chou-Talalay methods describing Log(Fa/Fu)5 mLog(Dx)– Log(Dm),
IC50 values taken from Dm calculations
Sample IC50 value (mg/ml)
CPT-UM 26
CPT-PEG 650
CPT-FA 560
FIGURE 6 Idealized co-culture devices cultured with Eahy.926 and 4T1 imaged at 10x with cell death/live fluorescent indicator dyes. Live
cell/Green Channel and Dead cell/Red Channel depicted at t548 hr: (a) control ICD and a (b) test ICD
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significantly more prominent compared to the cancer cell chamber. For
example, CPT-UM exhibited over 100-fold increase in dead/live ratio
for endothelial cells. This clearly indicates that CPT nanoparticles are
significantly more effective in killing endothelial cells compared to can-
cerous cell mass cells. CPT-PEG also yielded a significant effect on cell
viability in cancerous cell mass and vascular channels. Conversely, a rel-
atively small effect was seen for CPT-FA in either channel (Figure 7).
The effect of CPT is distributed throughout the cancerous cell mass
and cytotoxicity is observed even at the middle of the cancer cell
chamber. No strong spatial dependence of anti-cancerous cell mass
activity of CPT nanocrystals was found (Figure 7).
3.4 | Nanocrystal penetration within idealized
co-culture microfluidic devices
To assess the correlation between the cytotoxicity of CPT nanocrystals
and their cancerous cell mass penetration, we assessed migration of
CPT-UM in ICDs with an intact endothelial barrier in the vascular chan-
nel. CPT-UM nanocrystals were localized largely in the vascular channel
and no clear penetration was observed into the cancer cell chamber
(Figure 8a). To assess whether the limited penetration originated from
the endothelial layer, the same experiments were performed using
ICDs without endothelial cells. Clear penetration of CPT-UM was seen
in the ICDs in the absence of endothelial cells (Figure 8b). Migration of
CPT-UM could be clearly seen through the slits into the inner chamber.
Penetration of CPT even deep within the inner chamber could be seen.
Zoomed views of the endothelial-cancerous cell mass interface further
clarify this observation (Figure 9a,b). In the absence of endothelial cells
CPT nanocrystals could be seen to penetrate through the slits and
appear within the cancer cell chamber (Figure 9b). In the presence of
endothelial cells, very limited penetration of CPT-UM could be seen in
the slits and no visible penetration could be seen within the cancer cell
chamber (Figure 9a). These results clearly show that endothelial cells
pose a barrier for nanoparticle transport into the cancerous cell mass.
4 | DISCUSSION
Nanoparticles developed for therapeutic applications typically advance
through the canonical channels of drug delivery research, whereby the
core platform is developed in vitro and then shunted into in vivo
research routes. This serial assessment is not ideal and limits the likeli-
hood of successful outcomes.1–3,20–26 This study aims to couple con-
ventional in vitro assays with microfluidics to assess nanoparticle
FIGURE 7 Effect on cell death in (a) 4T1 cells, cancerous cell mass channel, whereby CPT FA and (b) Eahy.926 cells, endothelial channel.
Cells were cultured in n53 idealized co-culture microfluidic devices. CPT-UM, CPT-PEG, and CPT-FA were flowed at 4 ll/min to a total
volume of 500 ll. Devices were incubated for 48 hr before being stained with cell death/live indicator dyes or stains
FIGURE 8 A co-culture idealized microfluidic device coated with a fibronectin basement membrane was imaged immediately after flow
(t50 hr) with CPT-UM crystals under the Near UV Channel at 4x and 10x as depicted from left to right to track the progress of the
CPT-UM UV fluorescent nanocrystals through the outer channel into the inner tissue culture chamber. Fluorescent images obtained on an
Olympus CKX-41. (a) ICD with endothelial cells. (b) ICD without endothelial cells
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penetration, diffusion, and eventual killing of a localized cancerous cell
mass while being subjected to physiologically relevant shear stresses,
approximately 1 dyne/cm2, in a three-dimensional co-culture cellular
environment. Shear stresses were calculated using the Haagen–Pois-
seuille equation.
Three nanocrystal platforms were chosen CPT-UM, CPT-PEG, and
CPT-FA for studies. While the purpose of the PEG-coating on the
nanocrystals was to extend their half-life in vivo,19,27–29 we sought to
assess whether the PEG coating would impact dissolution and penetra-
tion. Conjugation to folic acid was aimed to improve targeting to folic
acid receptors which are known to be upregulated or expressed in
breast cancer lines, 4T1 cells included.14,16,30
All three nanocrystalline constructs were imaged under SEM to
verify their nanorod morphology. As the complexity of the scaffold
increased so did their size and charge. Their overall charge remained
negative, which has significant implications in their toxicity, uptake, and
penetration both in vitro and within the ICDs.31–35
Studies described here demonstrate the use of microfluidic co-
culture devices to assess efficacy of nanoparticles and potentially
other therapeutics while subjected to flow. The primary distinctive
result obtained with microfluidic devices is the lack of nanoparticle
penetration deep into the cancerous cell mass. Whereas the nano-
particles readily traversed into the center of the device in the
absence of the endothelial layer, minimal penetration was seen in
the presence of endothelial cells. These studies verify the presence
of a barrier created by the endothelial cells for nanoparticle pene-
tration (Supporting Information Figures 4 and 5). Nevertheless, a
clear effect of CPT on survival of cancer cells was observed. In fact,
the cytotoxic effect of CPT was seen through the cancerous cell
mass, even at the center of the cancerous cell mass. These results
suggest that CPT nanocrystals likely dissolve near the periphery of
the cancerous cell mass and diffusion of molecular CPT is responsi-
ble for cytotoxic effect. This is consistent with the observation that
LC50 of CPT nanocrystals correlated with their dissolution rates.
CPT-UM constructs exhibited the highest therapeutic efficacy (Fig-
ure 8). The in vitro cell viability data correlated well with the ICD
cell viability data. CPT-PEG and CPT-FA exhibited lesser efficacy
than CPT-UM likely due to these constructs’ slower dissolution
(Figure 5). The presence of the PEG-Folate construct in CPT-FA
nanocrystals was able to reduce nonspecific death observed within
the vascular channels (Supporting Information Figure 3).
The data presented here confirm the potential of CPT nanocrystal-
line scaffolds for cancerous cell mass treatment. The nanocrystals were
delivered under a bolus injection-like infusion method. While minimal-
to-none penetration of CPT nanocrystals was found in the cancerous
cell mass, sufficient amount appeared to cross the endothelium to treat
cancer cells. The limited ability of nanocrystals to penetrate into the
cancerous cell mass did not appear to originate from the challenge of
margination/wall contact. Specifically, in the absence of endothelial
cells, nanocrystals readily penetrated into the cancer cell chamber. The
primary resistance appeared to arise from the endothelial cell barrier.
The ICD’s ability to provide insight into carrier behavior under these
complex conditions cannot be tested in static in vitro cell culture. The
overarching combined results from the in vitro cell culture and the ICD
data lead to the conclusion that modest amounts of nanocrystals dif-
fuse into the periphery of the cancerous cell mass site which dissolve
and supply drug deep into the cancerous cell mass.9 It is the diffusion
of small molecule, which results in cell death throughout the entirety of
the cancer cell chamber.
Dissolution of nanocrystals appears to play a key role in its efficacy
since the nanocrystals themselves were unable to penetrate deep
within the cancerous cell mass. CPT-UM nanocrystals had the highest
release rates of CPT. The release profile data suggested that CPT’s
increased solubility arose from its interactions with serum proteins.36,37
Nanocrystalline constructs containing PEG or PEG-FA coating exhib-
ited increased IC50 values compared to CPT-UM. Folate receptors
(FR’s) are known to be overexpressed in a variety of breast cancer cell
lines.16 For 4T1 cells, FR’s are also slightly overexpressed on their cell
surfaces.14 Some decrease in IC50 value was seen for CPT-FA com-
pared to CPT-PEG, thus suggesting the role of FA targeting. However,
the effect was modest, thus indicating that the primary effect of CPT
appears to be through drug dissolution.
FIGURE 9 A co-culture idealized microfluidic device coated with a fibronectin basement membrane was imaged immediately after flow
(t50 hr) with CPT-UM crystals under the Near UV Channel at 20x as depicted from left to right to track the progress of the CPT-UM UV
fluorescent nanocrystals through the outer channel into the inner tissue culture chamber. Fluorescent images obtained on an Olympus
CKX-41. (a) ICD with endothelial cells. (b) ICD without endothelial cells
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Nanocrystals provide an attractive platform for delivery of highly
hydrophobic drugs. In addition to validating and rigorously analyzing
CPT nanocrystalline constructs for their properties and performance in
vitro, this study aimed to provide an additional cellular analytical tool
to help bridge the gap between in vitro characterization and develop-
ment and in vivo testing. Cell viability data obtained using the idealized
co-culture microfluidic devices cultured with both 4T1 breast cancer
and Ea.hy926 endothelial cells in a three-dimensional construct, in
close cellular contact and with flow and shear stress factors included,
was insightful and supports that notion of superficial yet impactful
delivery of nanocrystals. The CPT nanocrystals’ capacity to induce sig-
nificant levels of cell death within the cancerous cell mass supports fur-
ther development for in vivo assessment.
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